Overall rank by patents
#24,549
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Imago Biosciences, Inc.
USPTO PatentsView assignee record - 11 granted patents across 6 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
11
Total patents granted
6
CPC technology areas
24.0
Avg claims per patent
+75%
5-year filing velocity
The verdict
Imago holds 11 US patents across 6 technology areas, rank #24,549 of 50,000 tracked assignees.
- #24,549
- of 50,000 US assignees by volume
- Top 24%
- by Innovation Score (45.0/100)
- 24.0
- avg claims per patent
- +75%
- filing velocity, last 5 yrs
Portfolio overview
Imago Biosciences, Inc. has been granted 11 US utility patents between 2017 and 2024, placing Imago Biosciences, Inc. at rank #24,549 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Imago Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Imago sits between Igisu Co., Ltd. (11 patents, rank #24,545) and Industrilås I Nässjö Aktiebolag (11 patents, rank #24,553) - the closest US assignees by grant volume. The composite Innovation Score of 45.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Imago Biosciences, Inc.'s 24.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Imago Biosciences, Inc. against peers pursuing similar technology classes.
Who files at Imago's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Igisu
Igisu Co., Ltd.
11 patents
- Ignite Scalarc So…
Ignite ScalArc Solutions, Inc.
11 patents
- Iguazio Systems
Iguazio Systems Ltd.
11 patents
- Imagescan
ImageScan, Inc.
11 patents
- Incarda Therapeut…
InCarda Therapeutics, Inc.
11 patents
- Indian Ocean Medi…
Indian Ocean Medical Inc.
11 patents
- Indorma Ventures…
Indorma Ventures Oxides LLC
11 patents
- Industrilås i Näs…
Industrilås i Nässjö Aktiebolag
11 patents
- Imago Biosciences ◀
Imago Biosciences, Inc.
11 patents
What this shows Imago holds 11 patents at rank #24,549, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Imago's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 24% higher than 76% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 9.1% |
| 2018 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2021 | 1 | 9.1% |
| 2022 | 2 | 18.2% |
| 2023 | 3 | 27.3% |
| 2024 | 1 | 9.1% |
Which technologies does Imago Biosciences, Inc. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Imago Biosciences, Inc. hold?
Imago Biosciences, Inc. holds 11 US granted patents filed between 2017 and 2024, spanning 6 technology areas.
What is Imago Biosciences, Inc.'s Innovation Score?
Imago Biosciences, Inc. has an Innovation Score of 45.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Imago Biosciences, Inc. focus on?
Imago Biosciences, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 11 patents. The company has filed patents in 6 CPC subclasses total.
Is Imago Biosciences, Inc.'s patent filing rate increasing or decreasing?
Imago Biosciences, Inc.'s recent filing velocity is +75% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Imago Biosciences, Inc.'s patents?
Imago Biosciences, Inc.'s patents average 24.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Imago Biosciences, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Imago's 11 grants land it in the top 24% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Imago ranks #24,549 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.